Neuroleptic discontinuation in clinical and research settings: Scientific issues and ethical dilemmas

Biological Psychiatry

Volumn 46, Issue 8, 1999, Pages 1050-1059

  Jeste, Dilip V ^a,b   Palmer, Barton W ^a   Harris, M Jackuelyn ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Antipsychotics; Pharmacologic treatment; Psychoses; Relapse; Schizophrenia; Tardive dyskinesia

Indexed keywords

NEUROLEPTIC AGENT;

CONFERENCE PAPER; DRUG THERAPY; ETHICS; HUMAN; MENTAL DISEASE; OUTPATIENT; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0032831993     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00208-5     Document Type: Conference Paper

References (63)

1. Neurological syndromes associated with antipsychotic drug use. Arch Gen Psychiatry. 28:1973;463-467.
2. Baldessarini R.J., Cole J.O., Davis J.M., Gardos G., Preskorn S.H., Tarsy D. Tardive Dyskinesia A Task Force Report of the American Psychiatric Association . 1980;American Psychiatric Association, Washington, DC.
3. Baldessarini R.J., Viguera A.C. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry. 52:1995;189-192.
4. Belitsky R., McGlashan T.H. At issue The manifestations of schizophrenia in late life: A dearth of data . Schizophr Bull. 19:1993;683-685.
5. Benes F.M., Paskevich P.A., Davidson J., Domesick V.B. The effects of haloperidol on synaptic patterns in the rat striatum. Brain Res. 329:1985;265-274.
6. Bleuler M. The Schizophrenic Disorders Long-term Patient and Family Studies. Translated by S.M. Clemens . 1978;Yale University Press, New Haven and London.
7. Breggin P.R. Brain-Disabling Treatments in Psychiatry Drugs, Electroshock, and the Role of the FDA . 1997;Springer, New York.
8. Bustillo J., Buchanan R., Irish D., Brerer A. Differential effect of clozapine on weight A controlled study . Am J Psychiatry. 153:1996;817-819.
9. Carpenter W.T., Hanlon T.E., Heinrichs D.W., et al. Continuous versus targeted medication in schizophrenic outpatients Outcome results . Am J Psychiatry. 147:1990;1138-1148.
10. Cassens G., Inglis A.K., Appelbaum P.S., Gutheil T.G. Neuroleptics Effects on neuropsychological function in chronic schizophrenic patients . Schizophr Bull. 16:1990;477-499.
11. Ciompi L. Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophr Bull. 6:1980;606-618.
12. Cohen S., Chiles J., MacNaughton A. Weight gain associated with clozapine. Am J Psychiatry. 147:1990;503-504.
13. Engstrom F. Psychotropic drugs Modern medicine's alternative to purgatives, straightjackets, and asylums . Postgrad Med. 101:1997;198-211.
14. Frankenburg F.R., Zanarini M.C., Kando J., Centorrino F. Clozapine and body mass change. Biol Psychiatry. 43:1998;520-524.
15. Gilbert P.L., Harris M.J., McAdams L.A., Jeste D.V. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry. 52:1995;173-188.
16. Glazer W.M., Johnstone B.M. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry. 58:1997;50-54.
17. Green M.F. Schizophrenia from a Neurocognitive Perspective Probing the Impenetrable Darkness . 1998;Allyn and Bacon, Boston.
18. Harding C.M., Brooks G.W., Ashikaga T., et al. The Vermont longitudinal study II. Long-term outcome of subjects who once met the criteria for DSM-III schizophrenia . Am J Psychiatry. 144:1987;727-735.
19. Harris M.J., Heaton R.K., Schalz A., Bailey A., Patterson T.L. Neuroleptic dose reduction in older psychotic patients. Schizophr Res. 27:1997;241-248.
20. Harvey P.D., Howanitz E., Parrella M., et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia A comparison across treatment sites . Am J Psychiatry. 155:1998;1080-1086.
21. Harvey P.D., Parrella M., White L., Mohs R.C., Davidson M., Davis K.L. Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res. 35:1999;77-84.
22. Inderbitzin L.B., Lewine R.R., Scheller-Gilkey G., et al. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. Am J Psychiatry. 151:1994;1753-1759.
23. Jeste D.V., Gilbert P.L., McAdams L.A., Harris M.J. Considering neuroleptic maintenance and taper on a continuum Need for individual rather than dogmatic approach . Arch Gen Psychiatry. 52:1995;209-212.
24. Jeste D.V., Gillin J.C., Wyatt R.J. Serendipity in biological psychiatry - A myth? Arch Gen Psychiatry. 36:1979;1173-1178.
25. Jeste D.V., Lacro J.P., Palmer B., Rockwell E., Harris M.J., Caligiuri M.P. Incidence of tardive dyskinesia in early stages of neuroleptic treatment for older patients. Am J Psychiatry. 156:1999;309-311.
26. Jeste D.V., Lacro J.P., Bailey A., Rockwell E., Harris M.J., Caligiuri M.P. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc. 47:1999;716-719.
27. Jeste D.V., Lohr J.B., Manley M. Study of neuropathologic changes in the striatum following 4-, 8- and 12-months of treatment with fluphenazine in rats. Psychopharmacology. 106:1992;154-160.
28. Jeste D.V., Palmer B.W. Secondary psychoses An overview . Semin Clin Neuropsychiatry. 3:1998;2-3.
29. Jeste D.V., Wyatt R.J. Understanding and Treating Tardive Dyskinesia. 1982;Guilford Press, New York.
30. Kane J.M., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment resistant schizophrenic A double-blind comparison with chlorpromazine . Arch Gen Psychiatry. 45:1988;789-796.
31. Kane J.M., Rifkin A., Woerner M., et al. Low-dose neuroleptic treatment of outpatient schizophrenics. Arch Gen Psychiatry. 40:1983;893-896.
32. Kane J.M., Woerner M., Lieberman J. Tardive dyskinesia Prevalence, incidence, and risk factors . J Clin Psychopharmacol. 8:1988;52S-56S.
33. Keks N.A. Impact of newer antipsychotics on outcomes in schizophrenia. Clin Ther. 19:1997;148-158.
34. Klapow J.C., Evans J., Patterson T.L., Heaton R.K., Koch W.L., Jeste D.V. Direct assessment of functional status in older patients with schizophrenia. Am J Psychiatry. 154:1997;1022-1024.
35. Koval M., Rames L.J., Christie S. Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry. 151:1994;1520-1521.
36. Kraus T., Haack M., Schuld A., et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry. 156:1999;312-314.
37. Lamberti J.S., Bellnier T., Schwarzkopf S.B. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry. 149:1992;689-690.
38. Lehmann H.E., Ban T.A. The history of the psychopharmacology of schizophrenia. Can J Psychiatry. 42:1997;152-162.
39. Lieberman J.A., Saltz B.L., Johns C.A., Pollack S., Borenstein M., Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 158:1991;503-510.
40. Lipton A., Cancro R. Schizophrenia Clinical features . Kaplan H.I., Saddock B.J. Comprehensive Textbook of Psychiatry. 6th edition. 1995;968-987 Williams & Wilkins, Baltimore, MD.
41. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 151:1994;825-835.
42. Marder S.R., Van Putten T., Mintz J., et al. Low and conventional dose maintenance therapy with fluphenazine decanoate Two year outcome . Arch Gen Psychiatry. 44:1987;510-517.
43. McGlashan T.H. A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull. 14:1988;515-542.
44. Meltzer H.Y., Fibiger H.C. Olanzapine A new atypical antipsychotic drug . Neuropsychopharmacology. 14:1996;83-85.
45. Meshul C.K., Casey D.E. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res. 489:1989;338-346.
46. Meyer J.M., Simpson G.M. From chlorpromazine to olanzapine A brief history of antipsychotics . Psychiatr Ser. 48:1997;1137-1139.
47. Nasar S. A Beautiful Mind. 1998;Simon & Schuster, New York.
48. National Bioethics Advisory Commission (1998): Research involving persons with mental disorders that may affect decision-making capacity. Volume 1. Report of the Recommendations of the National Bioethics Advisory Commission. Rockville, Maryland.
49. National Bioethics Advisory Commission (1999): Research involving persons with mental disorders that may affect decision-making capacity. Volume 2. Commissioned papers by the National Bioethics Advisory Commission. Rockville, Maryland.
50. Peterson G., Byrd S. Diabetic ketoacidosis from clozapine and lithium co-treatment. Am J Psychiatry. 153:1996;737-738.
51. Popli A.P., Konicki P.E., Jurjus G.J., Fuller M.A., Jaskiw G.E. Clozapine and associated diabetes mellitus. J Clin Psychiatry. 58:1997;108-111.
52. Schonecker M. Ein eigentumliches Syndrom im oralen Bereich bei Megaphen Applikation. Nervenarzt. 28:1957;35.
53. Schooler N. Maintenance treatment of schizophrenia A review of dose reduction and family treatment strategies . Psychiatr Q. 66:1995;279-292.
54. Sigwald J., Bouttier D., Raymondeaud C. Quatre cas de dyskinesie facio-bucco-lingui-mastricatrice a evolution prolongee secondaire a un traitment par les neuroleptiques. Rev Neurol. 100:1959;751-755.
55. Small J.G., Hirsch S.R., Arvanitis L.A., Miller B.G., Link C.G.G. Quetiapine in patients with schizophrenia. Arch Gen Psychiatry. 54:1997;549-557.
56. Spohn H.E., Strauss M.E. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol. 98:1989;367-380.
57. Tancredi L.R. Malpractice and tardive dyskinesia A conceptual dilemma . J Clin Psychopharmacol. 8:1988;71S-76S.
58. Thomas C.S., Lewis C.S. Which atypical antipsychotic [editorial]? Br J Psychiatry. 172:1998;106-109.
59. Tollefson G.D., Beasley C.M., Tamura R.N., Tran P.V., Potvin J.H. Blind, controlled, long-term study of the comparative incidence of treatment-emerged tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 154:1997;1248-1254.
60. Umbricht D.S.G., Pollack S., Kane J.M. Clozapine and weight gain. J Clin Psychiatry. 59:(suppl B):1994;157-160.
61. Viguera A.C., Baldessarini R.J., Hegarty J.D., van Kammen D.P., Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 54:1997;49-55.
62. Wirshing D.A., Spellberg B.J., Erhart S.M., Marder S.R., Wirshing W.C. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 44:1998;778-783.
63. Woerner M.G., Alvir J.M., Saltz B.L., Lieberman J.A., Kane J.M. Prospective study of tardive dyskinesia in the elderly Rates and risk factors . Am J Psychiatry. 155:1998;1521-1528.